Investigating how TLE1 affects the aggressiveness of lung adenocarcinoma
Official title: Role of the transcriptional corepressor TLE1 in the lung adenocarcinoma aggressiveness and progression
Funded at Xavier University of Louisiana · NIH-11081675 · Data updated 2026-11-12
This study is looking at a protein called TLE1 to see how it helps lung adenocarcinoma cells survive and grow, even when they usually shouldn't, with the hope of finding new ways to treat this tough type of lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xavier University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | June 1, 2022 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $146,314 |
| NIH project number | 5R16GM145484-04 |
| Project ID | NIH-11081675 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with lung adenocarcinoma, particularly those with aggressive forms of the disease.
✕Less likely to help
Patients with other types of lung cancer or those without a diagnosis of lung adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on understanding the role of a protein called TLE1 in lung adenocarcinoma, a type of lung cancer known for its aggressive nature. The study aims to explore how TLE1 contributes to cancer cell survival and growth, particularly in conditions that typically lead to cell death. By examining the molecular mechanisms involved, including the interaction with other genes and proteins, the research seeks to identify potential targets for new cancer therapies. Patients may benefit from insights gained that could lead to improved treatment strategies for lung adenocarcinoma.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that improve survival rates for patients with lung adenocarcinoma.
How similar studies have gone: Previous research has shown promising results in targeting similar molecular pathways in cancer treatment, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
-
Xavier University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Biliran, Hector Ramos — Xavier University of Louisiana
- Study coordinator: Biliran, Hector Ramos
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.